SCHEMBL7718953

SCHEMBL7718953

CCCC(CC(=O)OCC)P(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
TSHR P16473 2/20 0.42
CYP3A4 P08684 2/20 0.42
ALOX15 P16050 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
FDPS P14324 4/20 0.42
METAP1 P53582 2/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CHRM1 P11229 1/20 0.38
ADORA1 P30542 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TRPA1 O75762 1/20 0.38
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7715963 0.89 FDPS (0.46) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL27738144 0.86 FDPS (0.49) FDPS
SCHEMBL27738148 0.86 FDPS (0.49) FDPS
SCHEMBL7716766 0.85 ALDH1A1 (0.45) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL7452145 0.84 L3MBTL1 (0.44) ALDH1A1TSHRCYP3A4ALOX15TDP1
Butane SCHEMBL9022466 0.82 MEN1 (0.37) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL4075525 0.78 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL235094 0.78 MGAM (0.48) ALDH1A1TSHRCYP3A4ALOX15TDP1
SCHEMBL8718703 0.76 FDPS (0.48) TDP1FDPSMETAP1CHRM1
SCHEMBL2545053 0.76 ALDH1A1 (0.47) ALDH1A1TSHRCYP3A4ALOX15TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed